View on GitHub

Added entries:

  • (FDA) EGFR exon 20 insertion variants and sensitivity to mobocertinib in non-small cell lung cancer.

Revised entries:

  • (FDA) BRCA1/2 pathogenic germline variants and sensitivity to talazoparib was revised to properly cite the package insert and correct a spelling error in the description.
  • (FDA) BCR-ABL1 and sensitivity to bosutinib in chronic myelogenous leukemia was revised to update the hyperlink for the package insert.
  • (FDA) BRAF p.V600E and sensitivity to encorafenib in melanoma was revised to update the hyperlink for the package insert.
  • (FDA) TMB-High and sensitivity to pembrolizumab in any solid tumor was revised to correct a spelling error in the description.